# Sandoz clinical trials: 139 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 139 trials with Sandoz as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sandoz: 139 rows for $6.95, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sandoz

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 139
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 139, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 31, 2025 | NCT07223294 | Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO... | Sandoz | Phase 3 | Withdrawn | Respiratory | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223294) |
| February 26, 2025 | NCT06847724 | Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With... | Sandoz | Phase 3 | Active not recruiting | Relapsing Multiple Sclerosis | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06847724) |
| September 19, 2024 | NCT06587451 | Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to... | Sandoz | Phase 3 | Terminated | Melanoma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06587451) |
| December 7, 2023 | NCT06159790 | A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated... | Sandoz | Phase 3 | Completed | Metastatic NSCLC | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06159790) |
| December 1, 2023 | NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II... | Sandoz | Phase 1 | Completed | Melanoma | 322 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06153238) |
| June 5, 2023 | NCT05887843 | Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal... | Sandoz | Phase 1 | Terminated | Seasonal Allergic Rhinitis | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05887843) |
| December 1, 2022 | NCT05633771 | Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting | Sandoz | Observational | Active not recruiting | Inflammatory Bowel Disease | 562 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633771) |
| October 21, 2022 | NCT05590598 | Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray... | Sandoz | Phase 3 | Completed | Seasonal Allergic Rhinitis | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05590598) |
| October 20, 2022 | NCT05588804 | Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections | Sandoz | Phase 3 | Completed | Acute Uncomplicated Respiratory Tract Infections | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05588804) |
| June 23, 2022 | NCT05429775 | In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects | Sandoz | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05429775) |
| April 5, 2022 | NCT05311475 | Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients... | Sandoz | Phase 3 | Completed | Seasonal Allergic Rhinitis | 669 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05311475) |
| March 16, 2022 | NCT05282004 | Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit | Sandoz | Phase 3 | Completed | Neovascular Age-related Macular Degeneration (nAMD) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05282004) |
| February 28, 2022 | NCT05258747 | A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg... | Sandoz | Phase 1 | Completed | Ovarian Cancer, Breast Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05258747) |
| December 17, 2021 | NCT05161806 | Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe | Sandoz | Phase 3 | Completed | Neovascular Age-related Macular Degeneration (nAMD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05161806) |
| October 7, 2021 | NCT05070650 | Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold | Sandoz | Phase 3 | Withdrawn | Common Cold | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05070650) |
| April 29, 2021 | NCT04864834 | Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related... | Sandoz | Phase 3 | Completed | Neovascular Age-related Macular Degeneration | 485 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04864834) |
| March 25, 2020 | NCT04321460 | Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults. | Sandoz | Phase 3 | Completed | Antibiotic-associated Diarrhea | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04321460) |
| December 3, 2019 | NCT04183634 | An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine. | Sandoz | Phase 1 | Terminated | Parkinson Disease | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04183634) |
| October 10, 2019 | NCT04123405 | Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis | Sandoz | Phase 3 | Completed | Rhinosinusitis | 944 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04123405) |
| September 11, 2019 | NCT04085809 | This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides... | Sandoz | Not applicable | Completed | Dry Skin | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04085809) |
| June 20, 2019 | NCT03993288 | Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable... | Sandoz | Phase 3 | Completed | Mild and Moderate Iron-deficiency Anaemia | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03993288) |
| June 7, 2019 | NCT03978494 | Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant... | Sandoz | Phase 1 | Withdrawn | Kidney Transplant | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03978494) |
| June 4, 2019 | NCT03974100 | Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal... | Sandoz | Phase 3 | Completed | Postmenopausal Women With Osteoporosis | 527 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03974100) |
| March 26, 2019 | NCT03890445 | Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease | Sandoz | Observational | Completed | Crohn´s Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03890445) |
| May 22, 2018 | NCT03531697 | Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery | Sandoz | Phase 1 | Completed | Inflammation Following Ocular Surgery | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03531697) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 84 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 36 |
| Phase 4 | 5 |
| Not applicable | 6 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 125 |
| Terminated | 8 |
| Withdrawn | 4 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Depression | 13 |
| HIV Infections | 10 |
| Hypertension | 9 |
| Renal Insufficiency, Chronic | 7 |
| Anemia | 7 |
| Acquired Immunodeficiency Syndrome | 7 |
| Cytopenia | 6 |
| Arthritis, Rheumatoid | 6 |
| Hypersensitivity | 5 |
| Breast Neoplasms | 5 |
| Neutropenia | 5 |
| Rhinitis, Allergic, Seasonal | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Inflammation | 4 |
| Leukopenia | 4 |
| Pain | 4 |
| Diarrhea | 4 |
| Prostatic Neoplasms | 3 |
| Infections | 3 |
| AIDS-Related Complex | 3 |
| Melanoma | 2 |
| Epilepsy | 2 |
| Bipolar Disorder | 2 |
| Chest Pain | 2 |
| Hirsutism | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Commercial real estate firms in the United States](https://specstream.ai/data/businesses/commercial-real-estate-firms/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [Chicken wings restaurants in the United States](https://specstream.ai/data/businesses/chicken-wings-restaurants/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
